Recruiting NCT03708627
Bimatoprost as a Treatment for Graves' Orbitopathy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Bimatoprost Ophthalmic.
- Who it may be relevant to
- Registry conditions: Graves Ophthalmopathy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Role of Bimatoprost in Graves' Periorbitopathy
Overview
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
Interventions
- Drug Bimatoprost Ophthalmic
Bimatoprost, aka Lumigan, one drop in one eye nightly
Primary outcome measures
- Reduction in periorbital fat causing improvement in proptosis [Time frame: 1 year]
Eligibility criteria
Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis -
Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- University of Washington — Seattle
Identifiers
NCT: NCT03708627 · IRB00294393